Back to News
Market Impact: 0.15
Perspective Therapeutics, Inc. Presents Incremental Phase 1/2a Data for [212Pb]Bamzireotide Navoxetan
Source: Nasdaq
Healthcare & Biotech
Perspective Therapeutics announced additional data and analyses from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors. The provided article text contains no efficacy, safety, or other numerical results, so the clinical significance cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)